Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016

被引:9
|
作者
Wongseelashote, Sarah [1 ]
Tayal, Vipin [2 ]
Bourke, Peter Francis [2 ,3 ]
机构
[1] Royal Darwin Hosp, Gen & Acute Care Med, Tiwi, NT, Australia
[2] Royal Darwin Hosp, Div Med Rheumatol, Tiwi, NT, Australia
[3] Cairns Hosp, Div Integrated Med & Emergency Serv Clin Immunol, Cairns, Qld, Australia
关键词
rituximab; autoimmune diseases; systemic lupus erythematosus; off-label; Aboriginal Australian; SYSTEMIC-LUPUS-ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; INDIGENOUS AUSTRALIANS; SUBOPTIMAL RESPONSE; EFFICACY; SAFETY; ENCEPHALITIS; CIDP; PREVALENCE;
D O I
10.1111/imj.13554
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundRituximab, an anti-CD20 B-cell depleting monoclonal antibody, is increasingly prescribed off-label for a range of autoimmune diseases. There has not previously been an audit of off-label rituximab use in the Northern Territory, where the majority of patients are Aboriginal. AimsTo evaluate retrospectively off-label rituximab use in autoimmune diseases in the Top End of the Northern Territory. MethodsWe performed a retrospective audit of 8 years of off-label rituximab use at the Royal Darwin Hospital, the sole tertiary referral centre for the Darwin, Katherine and East Arnhem regions. Electronic and paper records were reviewed for demographic information, diagnosis/indication for rituximab, doses, previous/concomitant immunosuppression, clinical outcomes and specific adverse events. ResultsRituximab was prescribed off-label to 66 patients for 24 autoimmune diseases. The majority of patients (62.1%) were Aboriginal and 60.6% female. The most common indications were refractory/relapsing disease despite standard therapies (68.7%) or severe disease with rituximab incorporated into an induction immunosuppressive regimen (19.4%). Systemic lupus erythematosus was the underlying diagnosis in 28.8% of cases. A clinically significant response was demonstrated in 74.2% of cases overall. There were 18 clinically significant infections; however, 13 were in patients receiving concurrent immunosuppressive therapy. There was a total of nine deaths from any cause. ConclusionRituximab has been used off-label for a range of autoimmune diseases in this population with a high proportion of Aboriginal patients successfully and safely in the majority of cases.
引用
收藏
页码:165 / 172
页数:8
相关论文
共 50 条
  • [1] Rituximab: A warning concerning off-label use
    Lynn, Shari J.
    [J]. AMERICAN JOURNAL OF NURSING, 2007, 107 (05) : 29 - 29
  • [2] Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases
    Ramos-Casals, M.
    Garcia-Hernandez, F. J.
    de Ramon, E.
    Callejas, J. L.
    Martinez-Berriotxoa, A.
    Pallares, L.
    Caminal-Montero, L.
    Selva-O'Callaghan, A.
    Oristrell, J.
    Hidalgo, C.
    Perez-Alvarez, R.
    Mico, M. L.
    Medrano, F.
    Gomez-de-la-Torre, R.
    Diaz-Lagares, C.
    Camps, M.
    Ortego, N.
    Sanchez-Roman, J.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (04) : 468 - 476
  • [3] Rituximab Off-label Maintenance Dosing in Systemic Autoimmune Rheumatic Disease: A Retrospective Review
    Kasprzak, Carolyn
    Barber, Claire
    Dersch-Mills, Deonne
    Charlton, Alexandra
    [J]. JOURNAL OF RHEUMATOLOGY, 2022, 49 (07) : 787 - 788
  • [4] Extent and patterns of off-label use of rituximab for SLE
    Iñaki Sanz
    [J]. Nature Reviews Rheumatology, 2016, 12 : 700 - 702
  • [5] Off-label use of rituximab in dermatology: pemphigus treatment
    Bomm, Lislaine
    Fracaroli, Taina Scalfoni
    Sodre, Joao Luz
    Bressan, Aline
    Gripp, Alexandre Carlos
    [J]. ANAIS BRASILEIROS DE DERMATOLOGIA, 2013, 88 (04) : 676 - 678
  • [6] Off-label use of rituximab in a tertiary Queensland hospital
    Butterly, S. J.
    Pillans, P.
    Horn, B.
    Miles, R.
    Sturtevant, J.
    [J]. INTERNAL MEDICINE JOURNAL, 2010, 40 (06) : 443 - 452
  • [7] Off-label use of rituximab in patients with multiple sclerosis
    Naegelin, Y.
    Kappos, L.
    [J]. MULTIPLE SCLEROSIS, 2009, 15 (09): : S123 - S123
  • [8] Off-Label Use of Rituximab in a Multipayer Insurance System
    Van Allen, Eliezer M.
    Miyake, Todd
    Gunn, Nathan
    Behler, Caroline M.
    Kohlwes, Jeff
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2011, 7 (02) : 76 - 79
  • [9] Extent and patterns of off-label use of rituximab for SLE
    Sanz, Inaki
    [J]. Nature Reviews Rheumatology, 2016, 12 (12) : 700 - U23